Stockhead journalist, Rob Badman, has reported on the upcoming LTR Pharma IPO today in an article title ‘Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX’.

Featuring highlights from a 1:1 interview with Alpine Capital‘s Co-Founder and Head of Institutional Sales, Phil Cawood, the article covers interesting ground about why LTR Pharma is ‘bucking the trend with a simple story’.

In the words of Phil:

“The Interest in LTP is there because it’s such a simple story people can understand and can readily see the use case for. You have a patent-protected product solving a very simple issue, which investors like. And you can pitch this story in one minute and everyone understands it straight away.”

Click here to read the Stockhead article.